Quick Answer
Clearside Biomedical, Inc. reported Diluted EPS of $0.47 per share (loss) for fiscal year 2024.
Clearside Biomedical, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.47 | +11.3% |
| 2023 | -$0.53 | +3.6% |
| 2022 | -$0.55 | -5600.0% |
| 2021 | $0.01 | +102.6% |
| 2020 | -$0.39 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.14 | +26.0% | -1800.0% |
| June 30, 2025 | -$0.06 | +40.0% | +45.5% |
| March 31, 2025 | -$0.11 | +35.3% | +92.9% |
| September 30, 2024 | -$1.54 | -926.7% | -1440.0% |
| June 30, 2024 | -$0.10 | +33.3% | +41.2% |
| March 31, 2024 | -$0.17 | -13.3% | -13.3% |
| September 30, 2023 | -$0.15 | -15.4% | +0.0% |
| June 30, 2023 | -$0.15 | -15.4% | +0.0% |
- Clearside Biomedical, Inc. showed an increase of +11.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, Clearside Biomedical, Inc.’s diluted eps has declined by 20.5% (from $0.39 per share (loss) to $0.47 per share (loss)).
- The most recent figure is from Clearside Biomedical, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: